PPARA and cardiac hypertrophy: The pathogenic activity of PPARα has been unequivocally demonstrated in transgenic mice with cardiac-specific overexpression of PPARα, which, similar to what we have described for ERRγ, develop ventricular hypertrophy and systolic dysfunction [24,25] and exhibit delayed postischemic recovery of cardiac function [26].